Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 8/20 | 0.65 |
| ▸ | THRB | P10828 | 8/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.65 |
| ▸ | AR | P10275 | 1/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 6/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813694 | 0.87 | THRA (0.65) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4899376 | 0.86 | THRA (0.64) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4812326 | 0.86 | THRA (0.64) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4887098 | 0.80 | THRA (0.69) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4898980 | 0.79 | THRA (1.00) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL14314183 | 0.78 | THRB (0.47) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4897130 | 0.74 | THRA (0.62) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4897125 | 0.74 | THRA (0.62) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4896830 | 0.74 | THRA (0.62) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4817169 | 0.74 | THRA (0.51) | THRATHRBESR1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319096-B2 | Thyroid hormone receptor antagonists for cardiac and metabolic disorders II | KARO BIO AB (SE) | 2008-01-15 | — | — | US | claimed |
| US-20040220147-A1 | Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll | KARO BIO AB (SE) | 2004-11-04 | — | — | US | claimed |
| EP-1387825-A1 | THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC & METABOLIC DISORDERS II | KARO BIO AB (SE) | 2004-02-11 | — | — | EP | claimed |
| WO-2002092550-A1 | THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC AND METABOLIC DISORDERS II | KARO BIO AB (SE) | 2002-11-21 | — | — | WO | claimed |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-7319096-B2 | Thyroid hormone receptor antagonists for cardiac and metabolic disorders II | KARO BIO AB (SE) | 2008-01-15 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
| US-20040220147-A1 | Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll | KARO BIO AB (SE) | 2004-11-04 | — | — | US | disclosed |
| EP-1387825-A1 | THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC & METABOLIC DISORDERS II | KARO BIO AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092550-A1 | THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC AND METABOLIC DISORDERS II | KARO BIO AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | THRA 559/4885THRB 792/4885ESR1 58/4885 |
| US-20040220147-A1 | Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll | TSHR, TRHR, THRA | THRA 3/4885THRB 4/4885ESR1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.